Work

Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor

Year: 2007

Type: article

Source: Molecular Cancer Therapeutics

Authors: Geoffrey I. Shapiro, Gerald M. Edelman, Emiliano Calvo, Sanjay Aggarwal, A. Douglas Laird

Institutions: Exelixis (United States), Mary Crowley Cancer Research Center, Dana-Farber Cancer Institute, Vall d'Hebron Hospital Universitari

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2272173799

FWCI: 0.655

Cites:

Cited by: 15

Related to: 10